The Production of High Purity Isotopes by Mass Separation for Medical Application (PRISMAS-MAP) project is a CERN coordinated H2020 project proposal in the submission stage. This integrating activity will mobilize a consortium of key research infrastructures in Europe. PRISMAS-MAP proposes to exploit the newly available mass separation technique at MEDICIS with other large European production infrastructures to foster a new research era based on emerging medical isotopes. The aim is to provide an improved access to new medical isotopes at a very high purity grade thanks to the close coordination and networking offered in the project. UL and RTU, with their expertise in clinical radiology, medical physics and nano-dosimetry, are contributing to this project in several work packages.
PRISMAS-MAP is a project proposal to be submitted under the H2020-INFRAIA-02-2020 call of the European Commission in March 2021. As described in the call, an Integrating Activity will mobilize a consortium of key research infrastructures in Europe. “The aim of this action is to bring together, integrate on European scale, and open up key national and regional research infrastructures to all European researchers, from both academia and industry, ensuring their optimal use and joint development”. The Integrating Activity shall combine Networking Activities (NA) to foster a culture of cooperation, transnational access or virtual access activities (TNA), to support scientific communities in their access to the identified key research infrastructures, and Joint Research Activities (JRA) to improve the integrated services provided.
PRISMAS-MAP proposes to exploit the newly available mass separation technique at MEDICIS with other large European production infrastructures to foster a new research era based on emerging medical isotopes. The aim is to provide improved access to new medical isotopes at very high purity grades thanks to the close coordination and networking offered in the project. As an example, a related coordinated infrastructure was proposed in the USA some years ago under the National Isotope Development Center (NIDC) from the DOE2. The definition of the large infrastructures and of the fully interconnected Networking Activities and Joint Research Activities will help shaping the European landscape to improve the access to new medical isotopes and purity grades for a starting researchers community involved in the development of radiopharmaceuticals for imaging and treatments, in the so-called fields of theranostics, targeted therapies and personalized medicine.
H2020 programme: INFRA-2-2020 call
Implementation stage: submitted
Project partners from Latvia: RTU, UL, Biomedical Engineering and Nanotechnologies Institute
Total project expenses: 5 M EUR
Project implementation period: starting from 2021
The project team of RTU:
Contacts: Jurijs Dehtjars ; Maija Radziņa m